Literature DB >> 33848766

Targeting Son of Sevenless 1: The pacemaker of KRAS.

Dirk Kessler1, Daniel Gerlach1, Norbert Kraut1, Darryl B McConnell2.   

Abstract

Son of Sevenless (SOS) is a guanine nucleotide exchange factor that activates the important cell signaling switch KRAS. SOS acts as a pacemaker for KRAS, the beating heart of cancer, by catalyzing the "beating" from the KRAS(off) to the KRAS(on) conformation. Activating mutations in SOS1 are common in Noonan syndrome and oncogenic alterations in KRAS drive 1 in seven human cancers. Promising clinical efficacy has been observed for selective KRASG12C inhibitors, but the vast majority of oncogenic KRAS alterations remain undrugged. The discovery of a druggable pocket on SOS1 has led to potent SOS1 inhibitors such as BI-3406. SOS1 inhibition leads to antiproliferative effects against all major KRAS mutants. The first SOS1 inhibitor has entered clinical trials for KRAS-mutated cancers. In this review, we provide an overview of SOS1 function, its association with cancer and RASopathies, known SOS1 activators and inhibitors, and a future perspective is provided.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cancer; KRAS; Medicinal chemistry; Protein–protein interaction; RASopathies; SOS1

Year:  2021        PMID: 33848766     DOI: 10.1016/j.cbpa.2021.02.014

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  8 in total

Review 1.  Emerging role of competing endogenous RNA and associated noncoding RNAs in thyroid cancer.

Authors:  Qian Bai; Zhenjie Pan; Ghulam Nabi; Farooq Rashid; Yang Liu; Suliman Khan
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

Review 2.  A pharmacological exploration of targeted drug therapy in non-small cell lung cancer.

Authors:  Ajay P Jayan; K R Anandu; Krishnadas Madhu; V N Saiprabha
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

Review 3.  Neurodevelopmental disorders, immunity, and cancer are connected.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  iScience       Date:  2022-05-30

4.  How can same-gene mutations promote both cancer and developmental disorders?

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Sci Adv       Date:  2022-01-14       Impact factor: 14.136

Review 5.  The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures.

Authors:  Miriam Grazia Ferrara; Alessio Stefani; Sara Pilotto; Carmine Carbone; Emanuele Vita; Mariantonietta Di Salvatore; Ettore D'Argento; Ileana Sparagna; Federico Monaca; Giustina Valente; Antonio Vitale; Geny Piro; Lorenzo Belluomini; Michele Milella; Giampaolo Tortora; Emilio Bria
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

6.  Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines.

Authors:  Adelina Plangger; Barbara Rath; Sandra Stickler; Maximilian Hochmair; Clemens Lang; Lukas Weigl; Martin Funovics; Gerhard Hamilton
Journal:  Discov Oncol       Date:  2022-09-01

Review 7.  Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.

Authors:  Thomas Yul Avery; Natalie Köhler; Robert Zeiser; Tilman Brummer; Dietrich Alexander Ruess
Journal:  Front Oncol       Date:  2022-07-27       Impact factor: 5.738

8.  Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.

Authors:  John M Ketcham; Jacob Haling; Shilpi Khare; Vickie Bowcut; David M Briere; Aaron C Burns; Robin J Gunn; Anthony Ivetac; Jon Kuehler; Svitlana Kulyk; Jade Laguer; J David Lawson; Krystal Moya; Natalie Nguyen; Lisa Rahbaek; Barbara Saechao; Christopher R Smith; Niranjan Sudhakar; Nicole C Thomas; Laura Vegar; Darin Vanderpool; Xiaolun Wang; Larry Yan; Peter Olson; James G Christensen; Matthew A Marx
Journal:  J Med Chem       Date:  2022-07-14       Impact factor: 8.039

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.